The observed divergence in mortality results when comparing injectable semaglutide to sitagliptin (a placebo proxy) in benchmarking analyses led us to view the results for outcomes containing mortality with skepticism and focused our interpretation on the nonmortality clinical endpoints
We are seeing more options, new mechanisms, and levels of efficacy that were unimaginable just a few years ago, including oral therapies and medications approaching weight loss previously seen only with surgery
J.Perez-RamirezC.CuraY.Carrasco-CamposM
[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Li B.X., Rognon G.T., Mattinson T., Vachali P.P., Gorusupudi A., Chang F.Y., Ranganathan A., Nelson K., George E.W., Frederick J.M., et al
Book your consultation today and take the first step towards radiant, glowing skin